바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Next
e-Submission

Vol.86 No.1
Citation Share

New Targeted Therapy for Non-Small Cell Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2023, v.86 no.1, pp.1-13
https://doi.org/10.4046/trd.2022.0066
Sang Hoon Lee (Division of Pulmonary, Department of Internal Medicine, Yonsei University College of Medicine)
Yong Seung Hyun (Division of Pulmonary, Department of Internal Medicine, Yonsei University College of Medicine)
Lee Eun Hye (Division of Pulmonary, Department of Internal Medicine, Yonsei University College of Medicine)
Kim Eun Young (Division of Pulmonary, Department of Internal Medicine, Yonsei University College of Medicine)
Chang Yoon Soo (Division of Pulmonary, Department of Internal Medicine, Yonsei University College of Medicine)
Chung Eun Ki (Division of Pulmonary, Department of Internal Medicine, Yonsei University College of Medicine)
Sang, H. L. , Yong, S. H. , Lee, E. H. , Kim, E. Y. , Chang, Y. S. , & Chung, E. K. (2023). New Targeted Therapy for Non-Small Cell Lung Cancer. Tuberculosis & Respiratory Diseases, 86(1), 1-13, https://doi.org/10.4046/trd.2022.0066
  • Downloaded
  • Viewed
PDF Download

Abstract

Lung cancer ranks first in cancer mortality in Korea and cancer incidence in Korean men. More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. Cytotoxic agents, targeted therapy, and immune checkpoint inhibitors are used in chemotherapy according to the biopsy and genetic test results. Among chemotherapy, the one that has developed rapidly is targeted therapy. The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. While previously targeted therapies have been developed for common genetic mutations, recently targeted therapies have been developed to overcome uncommon mutations or drug resistance that have occurred since previous targeted therapy. Therefore, this study describes recent, rapidly developing targeted therapies.

keywords
Carcinoma, Non-Small-Cell Lung, Molecular Targeted Therapy, Prognosis

Tuberculosis & Respiratory Diseases

e-Submission OA Policy